Ascletis Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASCLF research report →
About the company
Ascletis Pharma Inc. , a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus.
- CEO
- Jinzi J. Wu
- IPO
- 2019
- Employees
- 202
- HQ
- Hangzhou, ENG, CN
Price Chart
- Market Cap
- $1.42B
- P/E
- -27.24
- P/S
- 5174.31
- P/B
- 5.07
- EV/EBITDA
- -19.20
- Div Yield
- 0.00%
- Gross Margin
- 25.99%
- Op Margin
- -23853.94%
- Net Margin
- -17745.56%
- ROE
- -18.93%
- ROIC
- -24.90%
- Revenue
- $1.98M · 53.99%
- Net Income
- $-350,592,985 · -16.50%
- EPS
- $-0.36 · -20.00%
- Op Income
- $-471,274,213
- FCF YoY
- 3.75%
- 52W High
- $2.50
- 52W Low
- $1.15
- 50D MA
- $1.69
- 200D MA
- $1.71
- Beta
- 0.40
- Avg Volume
- 479
Get TickerSpark's AI analysis on ASCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ASCLF coverage
Recent articles, reports, and earnings notes.
No research on ASCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASCLF report →Similar companies
Peers in the same neighborhood.